IN VIVO’s Deals Of The Month: February 2016
IN VIVO’s editors pick February's top alliance, financing and M&A deals (free with registration).
You may also be interested in...
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
Barely a month after vowing to up investment in its surgical eye-care business, Novartis’ Alcon has signed a deal that will bring a new micro-stent technology into its glaucoma portfolio.
There is growing interest in the gut microbiome as a source of new therapies across a wide range of diseases. Although it is still an emerging field, pharmaceutical firms and other investors are engaging, with more expected to follow.